DB Pharm Korea is
Profile and Mission
Company Strategy
Company History
Leadership Team
Company History
2013 In November, DB Pharm and Zenics participate in the Annual Meeting of the Korean Society of Anesthesiologists, Nov. 7-9, Kangwon Land. At the Meeting, Caldolorбу booth and exhibition are arranged

In October, DB Pharm and Zenics participate in the Annual Meeting of the American Society of Anesthesiologists, Oct. 12-16, San Francisco. At the Meeting, Caldolorбу booth and exhibition are arranged and Caldolorбу studies are presented.

In September, DB Pharm participates in the 45th Congress of the International Society of Pediatric Oncology, Sep.24-28, Hong Kong.

In September, DB Pharm achieves first commercial sales of Caldolorбу (ibuprofen IV) through local distributor, Zenics Korea.

In July, DB Pharm launches Caldolorбу(ibuprofen IV) for the indications for reduction of fever and management of moderate to severe pain as an adjunct to opioid analgesics in Korea

In July, DB Pharm reaches Distribution Agreement with Zenics Korea for Caldolorбу (ibuprofen IV)

In June, DB Pharm receives HIRA decision on the reimbursement classification of Caldolorбу as non imbursement drug which means the drug cost would be covered by patient's oneself.

2012 In September, DB Pharm has changed representative director from K K Park & H K Lee to H K Park

In June, DB Pharm participates in the Symposium of the Korean Burn Society, June 14-15, Kim Koo Memorial Hall. At the Meeting, Caldolorбу booth and exhibition are arranged.

2011 In November, DB Pharm participates in the 52th Symposium of the Korean Society of Hematology, Nov.11-12, Songdo Convensia. At the Meeting, Caldolorбу booth and exhibition are arranged.

In May, DB Pharm receives KFDA approval for Hospira Cytarabine 100mg transferred from Pharma Research.

In January, DB Pharm receives KFDA approval for Caldolorбу (ibuprofen IV), a worldwide brand named NSAIDs for pain and fever patients.

2009 In December, DB Pharm reaches License and Distribution Agreement with Cumberland Pharmaceutical Inc. for the business of Caldolorбу in Korea market.

In September, DB Pharm reaches Promotion Agency Agreement with Hospira for three products {Cytarabine, Pentamidine & Nipentбу (pentostatin)} for five years.

In June, H K Lee, representative director, visits Cumberland Pharmaceutical Inc. and has business meeting with the CEO, Mr. A Z Kazimi, for the partnership of Cumberland products including Caldolorбу (ibuprofen IV).

2007 DB Pharm reaches new License Agreement with Hospira, an American multi-national company, for oncology & antidote injectables in Korea as Hospira acquired Mayne Pharma.
2004 DB Pharm receives KFDA approval for Anzataxбу (paclitaxel), a worldwide brand named anti-cancer drug, and launches it for the patients of lung, breast & ovarian cancer
2002 DB Pharm reaches new License Agreement with Mayne Pharma, an Australian multi-national company, for oncology & antidote injectables in Korea as Mayne Pharma acquired F H Faulding.
1999 DB Pharm Korea Co., Ltd. has established in Seoul. The company has licenses for consulting, importing, trading & whole selling of drug and health food. The founders are K K Park and H K Lee.
1997 Chung Woo achieves product registration approval form KFDA for three oncology products and one antidote and launched that in market under the name of HK Pharmed.
1996 Chung Woo Trading Company, predecessor of the present DB Pharm Korea Co., Ltd., reaches License Agreement with F H Faulding, an Australian multi-national company, for oncology & antidote injectables in Korea